Deals channel feed

Roche inks $308.6M col­lab­o­ra­tion deal with Lead Phar­ma, fo­cus­ing on im­mune-me­di­at­ed dis­ease

5 years ago

An ex-Vant fur­ther im­mers­es it­self in a new um­brel­la, cash­ing out in a $584M M&A deal with Sum­it­o­mo Dainip­pon sub­sidiary

5 years ago

No thanks: Roche backs out of EGFR-re­lat­ed pro­tein de­graders in re­vised deal with C4

5 years ago

UCB is beef­ing up its gene ther­a­py ops with back-to-back deals to buy a start­up and sign up a uni­ver­si­ty spin­out for dis­cov­ery work

5 years ago
Cell/Gene Tx

Cit­ing tox­i­c­i­ty con­cerns, Boehringer In­gel­heim drops short-lived IPF pact — keep­ing $1B+ in its pock­et

5 years ago

Vivek Ra­maswamy eyes an I/O vant with up to $2B li­cens­ing deal

5 years ago
People

No­vo Nordisk bolts on a ‘holy grail’ oral de­liv­ery plat­form in $1.8B buy­out

5 years ago

What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

5 years ago
Startups
R&D

In­spired by ASH da­ta, Mer­ck­'s Roger Perl­mut­ter swoops in with a $2.75B ROR1 buy­out aimed at beef­ing up the can­cer pipeline

5 years ago

Eye­ing com­mer­cial­iza­tion, a Shang­hai-based CAR-T start­up nabs a $186M megaround

5 years ago
China
Cell/Gene Tx

Sana Biotech­nol­o­gy snags Os­cine, adding cell ther­a­py leader Steve Gold­man to its star-stud­ded staff

5 years ago
Cell/Gene Tx

PerkinElmer buys out British gene edit­ing play­er for $383M, boost­ing its di­ag­nos­tics and ge­nom­ic ca­pa­bilites

5 years ago

Roy­al­ty Phar­ma tops its record-set­ting $3.3B deal with CF Foun­da­tion, bet­ting $575M more on Ver­tex's drugs

5 years ago

Joe Jimenez has one more thing to do in bio­phar­ma. And now he and Mark Fish­man have a $133M stake to play the start­up game

5 years ago
Financing

As­traZeneca sells off heart fail­ure and hy­per­ten­sion drugs to Chep­lapharm for $400M

5 years ago

Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard of care

5 years ago

No­var­tis buys a new gene ther­a­py for vi­sion loss, and this is one pre­clin­i­cal ven­ture that did­n't come cheap

5 years ago
Cell/Gene Tx

Sanofi teams up with Mer­ck to pair Keytru­da with a next-gen IL-2 can­di­date from the Syn­thorx buy­out

5 years ago
Pharma

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine learn­ing world

5 years ago
AI

Chi­nese rare dis­ease play­er inks first deal around nar­colep­sy drug Wak­ix af­ter grab­bing $80M to build an ecosys­tem

5 years ago
China

Eli Lil­ly lines up a block­buster deal for Covid-19 an­ti­body, right af­ter it failed a NI­AID tri­al

5 years ago

No­var­tis CEO Vas Narasimhan signs off on a $231M deal to try some­thing new in the R&D fight against SARS-CoV-2

5 years ago
Outsourcing
Coronavirus

So­bi bets $250M cash, about $1B in mile­stones for rights to a C3 ther­a­py be­ing pushed through 5 piv­otal tri­als

5 years ago

A month af­ter Il­lu­mi­na's big Grail buy­out, Ex­act Sci­ences scoops up liq­uid biop­sy ri­val Thrive for a rel­a­tive bar­gain

5 years ago
First page Previous page 83848586878889 Next page Last page
A service from the Financial Times